Co-diagnostics, inc. announces product launch of vector smart™ zdc test

Co-diagnostics, inc. announced the product launch of their vector smart™ zdc test, used to identify the presence of zika, dengue, and chikungunya in mosquito populations, in response to demand from domestic and foreign markets. the vector smart zdc multiplex test was created following requests from mosquito abatement districts and ministries of health throughout north america, latin america and the caribbean for a test that can accurately identify zika, dengue and chikungunya, but which is tailored specifically for mosquito populations. most polymerase chain reaction (pcr) assays used for mosquito testing were designed and validated for use on human samples. the company’s vector smart line of pcr products are validated using extractions from mosquito samples rather than humans and include an extraction control specifically for mosquitoes, to reduce the possibility of a false negative result due to an improper extraction. the company’s logix smart™ zdc test, which received ce-ivd approval earlier this year, served as a template for the initial design and development of the new vector smart product. also in development is another multiplex product for north america that includes eastern equine encephalitis (eee), a rare cause of brain infections that has been identified at a significantly higher occurrence than normal this year. eee has a high mortality rate of roughly 30%, and a high percentage of survivors have ongoing neurological problems as well.
CODX Ratings Summary
CODX Quant Ranking